Industry

-

Saniona has finalized preclinical development of its KCa3.1 inhibitor SAN903 for the treatment of inflammatory and fibrotic diseases

Source: Saniona

Ion Channel library
About
Credits

artem@ionchannellibrary.com

© 2023 Artem Kondratskyi

Terms of Use

Privacy policy